{"id":7248,"date":"2021-07-19T18:13:18","date_gmt":"2021-07-20T01:13:18","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7248"},"modified":"2023-06-26T14:31:49","modified_gmt":"2023-06-26T18:31:49","slug":"bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/","title":{"rendered":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease"},"content":{"rendered":"

CAMBRIDGE, Mass.,\u00a0July 19, 2021<\/strong>\u00a0\u2014 BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson\u2019s disease (PD). DA01, BlueRock\u2019s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study.<\/p>\n

The FDA\u2019s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate\u2019s development plan as well as eligibility for accelerated approval and priority review.<\/p>\n

\u201cReceiving Fast Track Designation from the FDA is an important step, which will help us further accelerate clinical development of our DA01 cell therapy approach for Parkinson\u2019s disease,\u201d says Joachim Fruebis, Ph.D., BlueRock\u2019s Chief Development Officer. \u201cThis is another critical step in the BlueRock mission to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition.\u201d<\/p>\n

About the Trial
\n<\/strong>The trial will enroll ten patients in\u00a0the United States\u00a0and\u00a0Canada. The primary objective of the\u00a0Ph1\u00a0study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. The secondary objectives of the study are to assess the evidence of transplanted cell survival and motor effects at one- and two-years post-transplant, to evaluate continued safety and tolerability at two years, and to assess feasibility of transplantation.<\/p>\n

More information about this trial is available at\u00a0clinicaltrials.gov<\/span><\/a>\u00a0(NCT#04802733).<\/p>\n

About Parkinson\u2019s Disease
\n<\/strong>Parkinson\u2019s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. At diagnosis, it is estimated that patients have already lost 60-80% of their dopaminergic neurons.\u00a0Parkinson\u2019s disease often starts with a tremor in one hand. Other symptoms are rigidity, cramping and dyskinesias. Parkinson\u2019s disease is the second most common neurodegenerative disorder, impacting more than 7.5 million people, including 1.3 million people in\u00a0North America.<\/p>\n

About BlueRock Therapeutics
\n<\/strong>BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. The company\u2019s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered for therapeutic purposes. The platform is broadly applicable, but the company is focused today in neurology, cardiology, immunology, and ophthalmology. In\u00a0August 2019, the company was acquired by Bayer Pharmaceuticals, for an enterprise value of\u00a0$1B\u00a0in upfront and milestone payments. For BlueRock this marks the next step in the journey to prove degenerative disease is reversible, and to bring our revolutionary new medicines to the patients who desperately need them. For more information, visit\u00a0www.bluerocktx.com<\/span><\/a>.<\/p>\n

About Bayer
\n<\/strong>Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help\u00a0people and planet thrive by supporting efforts to master\u00a0the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The\u00a0Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4\u00a0billion euros. R&D expenses before special items\u00a0amounted to\u00a04.9 billion euros.\u00a0For more information, go to\u00a0www.bayer.com<\/span><\/a>.<\/p>\n

Forward-Looking Statements
\n<\/em><\/strong>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on BlueRock\u2019s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing of our clinical trial for DA01; our results regarding the safety, tolerance and efficacy of DA01 cell transplantation for patients with Parkinson\u2019s disease; and ongoing FDA and other regulatory requirements regarding the development of DA01. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of the Company\u2019s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.,\u00a0July 19, 2021\u00a0\u2014 BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson\u2019s disease (PD). DA01, BlueRock\u2019s pluripotent stem […]<\/p>\n","protected":false},"author":2,"featured_media":7708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[45],"tags":[52,56,57],"class_list":["post-7248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases","tag-announcement","tag-neurology","tag-clinical-trials"],"acf":[],"yoast_head":"\nBlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.,\u00a0July 19, 2021\u00a0\u2014 BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson\u2019s disease (PD). DA01, BlueRock\u2019s pluripotent stem […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-20T01:13:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T18:31:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/\",\"url\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/\",\"name\":\"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"datePublished\":\"2021-07-20T01:13:18+00:00\",\"dateModified\":\"2023-06-26T18:31:49+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg\",\"width\":900,\"height\":1000,\"caption\":\"BlueRock Therapeutics Logo Card\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/","og_locale":"en_US","og_type":"article","og_title":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP","og_description":"CAMBRIDGE, Mass.,\u00a0July 19, 2021\u00a0\u2014 BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson\u2019s disease (PD). DA01, BlueRock\u2019s pluripotent stem […]","og_url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2021-07-20T01:13:18+00:00","article_modified_time":"2023-06-26T18:31:49+00:00","og_image":[{"width":900,"height":1000,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/","url":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/","name":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","datePublished":"2021-07-20T01:13:18+00:00","dateModified":"2023-06-26T18:31:49+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2023\/06\/BR-Logo-Card.jpg","width":900,"height":1000,"caption":"BlueRock Therapeutics Logo Card"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7248"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=7248"}],"version-history":[{"count":5,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7248\/revisions"}],"predecessor-version":[{"id":7632,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/7248\/revisions\/7632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/7708"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=7248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=7248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=7248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}